Cargando…

Properdin (factor P) as a new target cleaved by factor XIa: Intrinsic coagulation at the crossroads with inflammation

Detalles Bibliográficos
Autores principales:	Luo, Qi, Wenzel, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634820/ https://www.ncbi.nlm.nih.gov/pubmed/36349265 http://dx.doi.org/10.1002/rth2.12835

Ejemplares similares

Novel interaction of properdin and coagulation factor XI: Crosstalk between complement and coagulation
por: Heal, Samantha L., et al.
Publicado: (2022)

Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa
por: Donkor, David A., et al.
Publicado: (2017)

PROPERDIN FACTOR D : II. ACTIVATION TO D BY PROPERDIN
por: Fearon, Douglas T., et al.
Publicado: (1974)

At the Crossroads of Inflammation and Tumorigenesis
por: Cordon-Cardo, Carlos, et al.
Publicado: (1999)

Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation
por: Parunov, Leonid A., et al.
Publicado: (2023)

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
por: Thomas, Dirk, et al.
Publicado: (2021)

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy
por: Michels, Marloes A. H. M., et al.
Publicado: (2019)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Astrocytic TLR4 at the crossroads of inflammation and seizure susceptibility
por: Henneberger, Christian, et al.
Publicado: (2016)

THE PROPERDIN SYSTEM AND IMMUNITY : III. THE ZYMOSAN ASSAY OF PROPERDIN
por: Pillemer, Louis, et al.
Publicado: (1956)

THE PROPERDIN SYSTEM AND IMMUNITY : III. THE ZYMOSAN ASSAY OF PROPERDIN
por: Pillemer, Louis, et al.
Publicado: (1956)

THE PROPERDIN SYSTEM AND IMMUNITY : V. THE BACTERICIDAL ACTIVITY OF THE PROPERDIN SYSTEM
por: Wardlaw, Alastair C., et al.
Publicado: (1956)

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
por: Thomas, Dirk, et al.
Publicado: (2019)

The induction of macrophage spreading by factor B of the properdin system
Publicado: (1979)

THE PROPERDIN SYSTEM AND IMMUNITY : VI. THE INACTIVATION OF NEWCASTLE DISEASE VIRUS BY THE PROPERDIN SYSTEM
por: Wedgwood, Ralph J., et al.
Publicado: (1956)

p27kip1 at the crossroad between actin and microtubule dynamics
por: Rampioni Vinciguerra, Gian Luca, et al.
Publicado: (2019)

The epitranscriptome: At the crossroad of cancer prognosis
por: Di Fazio, Pietro
Publicado: (2021)

Interventional electrophysiology at a crossroads
por: Hauser, Robert G., et al.
Publicado: (2022)

Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances
por: Xia, Yunqing, et al.
Publicado: (2023)

QUANTITATIVE STUDIES ON THE PROPERDIN-COMPLEMENT SYSTEM : II. KINETICS OF THE REACTION BETWEEN PROPERDIN AND ZYMOSAN
por: Leon, Myron A.
Publicado: (1957)

Coagulation factor with potential for the treatment of heart failure
por: Cao, Yang, et al.
Publicado: (2022)

Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
por: Kar, Srabani, et al.
Publicado: (2020)

ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism
por: Porres-Aguilar, Mateo
Publicado: (2023)

AN ALTERNATIVE MECHANISM FOR THE PROPERDIN SYSTEM
por: Nelson, Robert A.
Publicado: (1958)

Properdin Levels in Human Sepsis
por: Stover, Cordula M., et al.
Publicado: (2015)

CCL2 at the crossroad of cancer metastasis
por: Eferl, Robert
Publicado: (2013)

Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant
por: Hamada, Mostafa, et al.
Publicado: (2021)

Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement
Publicado: (1976)

Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
por: Kastenhuber, Edward R, et al.
Publicado: (2022)

Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa
por: Kar, Srabani, et al.
Publicado: (2021)

Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors
por: Jones, Aaryana, et al.
Publicado: (2023)

Decision making in xia2
por: Winter, Graeme, et al.
Publicado: (2013)

In Memorium of Dr. Bing Xia
por: Qian, Jiaming, et al.
Publicado: (2015)

The Crossroads of the Coagulation System and the Immune System: Interactions and Connections
por: Wilhelm, Grzegorz, et al.
Publicado: (2023)

Comparative Thrombin Generation in Animal Plasma: Sensitivity to Human Factor XIa and Tissue Factor
por: Liang, Yideng, et al.
Publicado: (2023)

ARF1 at the crossroads of podosome construction and function
por: Genot, Elisabeth
Publicado: (2017)

At the crossroads of religion and palliative care in patients with dementia
por: Quinn, Kieran L., et al.
Publicado: (2020)

Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor
Publicado: (1975)

PROPERDIN FACTOR D: CHARACTERIZATION OF ITS ACTIVE SITE AND ISOLATION OF THE PRECURSOR FORM
por: Fearon, Douglas T., et al.
Publicado: (1974)

Properdin and Factor H: Opposing Players on the Alternative Complement Pathway “See-Saw”
por: Kouser, Lubna, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4k6s1ubk19bifjht5j0ms2bjtm